Bispecific antibodies (BsAbs) have been developed, with one antigen-binding site coordinated against the CD3 receptor (which activates cytotoxic T lymphocytes) and other specific antigens found on cancer cells (CD19, CD20, CD33, CD123, HER2, epithelial cell adhesion molecule [EpCAM], BCMA, CEA, others) [1].